×

Shares of Halozyme spike 17% after positive results for pancreatic cancer drug

Thursday, 5 Jan 2017 | 2:02 PM ET

Jim Cramer spoke with Halozyme Therapeutics' CEO on its results for phase 2 pancreatic cancer drug.